The growing biotechnology cluster in Pennsylvania has a new add-on, during summer 2023 opened the Strasbourg-based AdipoPharma SAS their first U.A. operation site in a former Pittsburgh regional hospital, their new home base for its clinical trials.
The French biotech company develops a drug that treats the affected patients’ insulin resistance, understanding the important role of the metabolic adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis – and commercializing now the long-term research work of its founder and President, Dr. Vincent Marion (PhD, MSc).
James Nolan, Chairman and CBO of AdipoPharma LLC, heads the company’s Pittsburgh operations. In addition of setting up the company’s US corporate office, the start-up looks forward to complete its staff with around 30 clinical trial specialists, partnering e.g. with the University of Pittsburgh and Carnegie Mellon University. The region’s life sciences reputation is full growth: Pittsburgh ranked 11th in JLL’s 2022 Life Sciences Research Outlook & Cluster Rankings, after not even being ranked the previous year. “The city has an abundance of research universities and thriving life sciences community. It’s also incredibly supportive to start-ups like AdipoPharma,” Nolan said. “Pittsburgh has a wealth of resources and scientific minds necessary for a company like AdipoPharma to grow.”
The leaders of AdipoPharma — with just secured funding, and its team of experienced researchers – and the biotech cluster in Pennsylvania will likely profit from each other.
Photo / Logo: ©2023 AdipoPharma SAS
More Posts
Weidmüller Group Bolsters U.S. Manufacturing with $16.4m Expansion in Virginia, adding over 100 jobs
